Copyright
©The Author(s) 2020.
World J Diabetes. Mar 15, 2020; 11(3): 66-77
Published online Mar 15, 2020. doi: 10.4239/wjd.v11.i3.66
Published online Mar 15, 2020. doi: 10.4239/wjd.v11.i3.66
Ref. | Country | Design | Time period | n | Average age (yr) | Number of controls | Methods | Lean mass | Fat mass | IR | WHR |
Studies in Transgender men | |||||||||||
Van Caenegem et al[41] | Belgium | Prospective controlled | 12 mo | 23 | 27 (9) | 23 age-matched | DXA and pQCT | ↑10.4% | ↓9.7% | ↔ | |
Haraldsen et al[31] | Norway | Prospective controlled | 3 mo, 12 mo | 21 | 25.1 (4.8) | 45, not age-matched | DXA | ↑ | ↔ | ||
Cupisti et al[24] | Germany | Prospective controlled | 12 mo | 29 | 29.9 (18-40) | 240 PCOS, age-matched | HOMA-IR | ↔ | |||
Aranda et al[19] | Spain | Prospective | 6 mo, 12 mo | 20 | 27.1 (8.0) | DXA and HOMA-IR | ↑5.8% | ↓6.3% | ↔ | ↑A:G ratio | |
Auer et al[21] | Germany | Prospective | 13 mo | 45 | 27.5 (1.3) | DXA and HOMA-IR | ↑ | ↓ | ↓ | ↔ | |
Klaver et al[32] | The Netherlands and Belgium | Prospective | 12 mo | 162 | 24 (18-58) | DXA | ↑10% | ↓9% | ↑ | ||
Gava et al[30] | Italy | Prospective | 12 mo, 36 mo, 60 mo | 50 | 30.1 (6.1) | DXA and HOMA-IR | ↑ | ↔ | ↔ | ↔ | |
Aranda et al[18] | Spain | Prospective | 6 mo, 12 mo | 12 | 27.1 (17-43) | HOMA-IR | ↔ | WC ↔ | |||
Auer et al[20] | Belgium and Norway | Prospective | 12 mo | 20 | NR | DXA and HOMA-IR | ↑ | ↔ | ↔ | ↔ | |
Colizzi et al[23] | Italy | Prospective | 12 mo, 24 mo | 43 | 28.8 (5.6) | HOMA-IR | ↔ | WC ↑ | |||
Pelusi et al[37] | Italy | Prospective | 30 wk, 54 wk | 45 | 29.5 | DXA and HOMA-IR | ↑ | ↓ | ↔ | ↔ | |
Wierckx et al[42] | Belgium | Prospective | 12 mo | 53 | 24.5 (7.0) | DXA | ↑ | ↓ | ↑ | ||
Mueller et al[35] | Germany | Prospective | 12 mo, 24 mo | 45 | NR | DXA | ↑ | ↔ | |||
Yahyaoui et al[43] | United States | Prospective | 12 mo, 24 mo | 47 | 25.7 (6.0) | HOMA-IR | ↓ | ||||
Merigg-iola et al[34] | Italy | Prospective | 12 mo | 15 | 35.7 (5.0) | DXA and HOMA-IR | ↑ | ↔ | ↔ | ↑ (NS) | |
Berra et al[22] | Italy | Prospective | 6 mo | 16 | NR | BIA and HOMA | ↑ | ↓ | ↔ | WC ↔ | |
Elbers et al[27] | The Netherlands | Prospective | 12 mo | 17 | 23 (16-34) | MRI and EGC | ↑ in VAT | ↔ | |||
Elbers et al[25] | The Netherlands | Prospective | 4 mo, 12 mo | 15 | 23 (16-34) | MRI and BIA | ↓ | ||||
Elbers et al[26] | The Netherlands | Prospective | 12 mo, 36 mo | 10 | 24 (16-33) | MRI | ↑ thigh muscle | ↑ in VAT | |||
Polderman et al[38] | The Netherlands | Prospective | 4 mo | 13 | 23.1 (18-33) | BIA and EGC | ↑ | ↑ | |||
Van Caenegem et al[39] | Belgium | Cross-sectional | 10 yr on GAHT (3-28) | 50 | 37 (8) | 50 age-matched | DXA and pQCT | 9% more | 30% less | Larger | |
Studies in Transgender women | |||||||||||
Haraldsen et al[31] | Norway | Prospective controlled | 3 mo, 12 mo | 12 | 29.3 (7.8) | 77, not age-matched | DXA | ↓ | ↑ | ||
Auer et al[21] | Germany | Prospective | 12 mo | 24 | 34.8(1.4) | DXA and HOMA-IR | ↔ | ↑ | ↑ | ↓ | |
Klaver et al[32] | The Netherlands and Belgium | Prospective | 12 mo | 179 | 29 (18-66) | DXA | ↓3% | ↑28% | ↓ | ||
Fighera et al[28] | Brazil | Prospective | 31 mo | 46 | 33.7 (10.3) | DXA | ↓ | ↑ | |||
Aranda et al[18] | Spain | Prospective | 6 mo, 12 mo | 6 | 18.8 (16-21) | HOMA-IR | ↔ | WC ↑ | |||
Auer et al[20] | Belgium and Norway | Prospective | 12 mo | 20 | NR | DXA and HOMA-IR | ↓ | ↑ | ↑ | ↔ | |
Gava et al[29] | Italy | Prospective | 12 mo | 40 | 31.2 (9.8) | DXA and HOMA-IR | ↓ (NS) | ↑ | ↔ | ↔ | |
Colizzi et al[23] | Italy | Prospective | 12 mo, 24 mo | 79 | 30.2 (9.6) | HOMA-IR | ↑ | WC ↑ | |||
Van Caenegem et al[40] | Belgium | Prospective | 12 months, 24 months | 46 | 33 (12) | 49 (not followed prospective-ly) | DXA and pQCT | ↓ | ↑ | ↓ | |
Wierckx et al[42] | Belgium | Prospective | 12 mo | 53 | 30.3 (14.0) | DXA | ↓ | ↑ | ↓ | ||
Mueller et al[36] | Germany | Prospective | 12 mo, 24 mo | 84 | NR | DXA | ↓ | ↑ | |||
Yahyaoui et al[43] | United States | Prospective | 12 mo, 24 mo | 22 | 23.1 (9.4) | HOMA-IR | ↔ | ||||
Elbers et al[27] | The Netherlands | Prospective | 12 mo | 20 | 26 (18-36) | MRI and EGC | ↑ VAT | ↑ | |||
Elbers et al[25] | The Netherlands | Prospective | 4 mo, 12 mo | 17 | 26 (18-37) | MRI and BIA | ↔ | ||||
Polderm-an et al[38] | The Netherlands | Prospective | 4 mo | 18 | 26.5 (18-36) | BIA and EGC | ↓ (NS) | ↑ | |||
Lapauw et al[33] | Belgium | Cross-sectional | 8 yr on GAHT (4-20) | 23 | 41 (7) | 46, age-matched | DXA, pQCT | 20% lower | 30% higher |
- Citation: Spanos C, Bretherton I, Zajac JD, Cheung AS. Effects of gender-affirming hormone therapy on insulin resistance and body composition in transgender individuals: A systematic review. World J Diabetes 2020; 11(3): 66-77
- URL: https://www.wjgnet.com/1948-9358/full/v11/i3/66.htm
- DOI: https://dx.doi.org/10.4239/wjd.v11.i3.66